Phaseline

Companies › VivaVision Biotech

VivaVision Biotech: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Infectious disease, Ophthalmology, Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VVN461 Ophthalmic Solution–Phase 3Non-infectious Anterior UveitisDec 2026
VVN001 Ophthalmic Solution, 5%–Phase 3Dry EyeApr 2027
VVN432 Nasal Spray–Phase 1Chronic Rhinosinusitis (CRS)Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07259538VVN432 Nasal SprayPhase 1Chronic Rhinosinusitis (CRS)RespiratoryNov 2026
NCT07136805VVN461 Ophthalmic SolutionPhase 3Non-infectious Anterior UveitisInfectious diseaseDec 2026
NCT06360133VVN001 Ophthalmic Solution, 5%Phase 3Dry EyeOphthalmologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Santen SAS Materia Medica Holding Joincare Pharmaceutical Group Industry Alimera Sciences Thirty Respiratory

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.